MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540128 | Name: Etretinate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etretinate is a RAR and RXR agonist previoulsy used to treat psoriasis. It induces brth defects and suppresses proliferation in cutaneous T-cell lymphoma models.

Chemical Structure

Etretinate
Etretinate
CAS#54350-48-0

Theoretical Analysis

MedKoo Cat#: 540128

Name: Etretinate

CAS#: 54350-48-0

Chemical Formula: C23H30O3

Exact Mass: 354.2195

Molecular Weight: 354.49

Elemental Analysis: C, 77.93; H, 8.53; O, 13.54

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 weeks
25mg USD 550.00 2 weeks
50mg USD 950.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tegison; Ethyl etrinoate; Etretinato; Retinoid; Etretinatum; NSC 297936; NSC297936; NSC-297936; Ro-10-9359; Ro 10-9359; Ro 10 9359; Ro109359
IUPAC/Chemical Name
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
InChi Key
HQMNCQVAMBCHCO-DJRRULDNSA-N
InChi Code
InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
SMILES Code
O=C(OCC)/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C=C(OC)C(C)=C1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 354.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Akasaka E, Mabuchi T, Manabe Y, Yahagi E, Yamada-Hiruma A, Yamaoka H, Kojima T, Kato M, Ikoma N, Ozawa A, Haruki Y. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. J Dermatol. 2013 Apr;40(4):238-43. doi: 10.1111/1346-8138.12069. Epub 2013 Jan 21. PubMed PMID: 23330814. 2: Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol. 1995 Jul;33(1):44-52. PubMed PMID: 7601945. 3: Larsen FG, Jakobsen P, Larsen CG, Nørgaard A, Kragballe K, Nielsen-Kudsk F. Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. Pharmacol Toxicol. 1987 Aug;61(2):85-8. PubMed PMID: 2959917. 4: Jakobsen P, Larsen FG, Larsen CG. Simultaneous determination of the aromatic retinoids etretin and etretinate and their main metabolites by reversed-phase liquid chromatography. J Chromatogr. 1987 Apr 10;415(2):413-8. PubMed PMID: 2953748. 5: Kochhar DM, Penner JD, Minutella LM. Biotransformation of etretinate and developmental toxicity of etretin and other aromatic retinoids in teratogenesis bioassays. Drug Metab Dispos. 1989 Nov-Dec;17(6):618-24. PubMed PMID: 2575497. 6: Browman GP, Arnold A, Booker L, Johnstone B, Skingley P, Levine MN. Etretinate blood levels in monitoring of compliance and contamination in a chemoprevention trial. J Natl Cancer Inst. 1989 May 10;81(10):795-8. PubMed PMID: 2654406. 7: Larsen FG, Jakobsen P, Larsen CG, Kragballe K, Nielsen-Kudsk F. Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. Pharmacol Toxicol. 1988 Mar;62(3):159-65. PubMed PMID: 2967472. 8: Bjerke JR, Geiger JM. Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients. Acta Derm Venereol Suppl (Stockh). 1989;146:206-7. PubMed PMID: 2532847. 9: Lawrence CM, Marks J, Parker S, Shuster S. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol. 1984 Feb;110(2):221-6. PubMed PMID: 6696838. 10: Shahidullah M, Tham SN, Goh CL. Etretinate therapy for psoriasis and other keratinizing disorders: a 10-year retrospective study in Singapore. Int J Dermatol. 1993 Sep;32(9):686-9. PubMed PMID: 7691773. 11: Giannetti A, Coppini M, Bertazzoni MG, Califano A, Altieri E, Pazzaglia A, Lega M, Lombardo M, Pelfini C, Veller Fornasa C, Rabbiosi G, Cespa M. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis. J Eur Acad Dermatol Venereol. 1999 Sep;13(2):91-5. PubMed PMID: 10568486. 12: Happle R, Traupe H, Bounameaux Y, Fisch T. [Teratogenic effects of etretinate in humans]. Dtsch Med Wochenschr. 1984 Sep 28;109(39):1476-80. German. PubMed PMID: 6479047. 13: Christiansen JV, Holm P, Reymann F, Thestrup-Pedersen K. Patients' acceptance of etretinate therapy. A retrospective survey of long-term etretinate therapy in chronic keratotic and pustular skin diseases. Dermatologica. 1984;168(3):122-6. PubMed PMID: 6714503. 14: Ellis CN, Hermann RC, Gorsulowsky DC, Goldfarb MT, Voorhees JJ. Etretinate therapy reduces inpatient treatment of psoriasis. J Am Acad Dermatol. 1987 Nov;17(5 Pt 1):787-91. PubMed PMID: 3680657. 15: Colburn WA, Gibson DM, Rodriguez LC, Buggé CJ, Blumenthal HP. Effect of meals on the kinetics of etretinate. J Clin Pharmacol. 1985 Nov-Dec;25(8):583-9. PubMed PMID: 3841130. 16: Rosén K, Mobacken H, Swanbeck G. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial. Arch Dermatol. 1987 Jul;123(7):885-9. PubMed PMID: 3300565. 17: DiGiovanna JJ, Gross EG, McClean SW, Ruddel ME, Gantt G, Peck GL. Etretinate: effect of milk intake on absorption. J Invest Dermatol. 1984 Jun;82(6):636-40. PubMed PMID: 6233379. 18: Lambert WE, Meyer E, De Leenheer AP, De Bersaques J, Kint AH. Pharmacokinetics and drug interactions of etretinate and acitretin. J Am Acad Dermatol. 1992 Dec;27(6 Pt 2):S19-22. PubMed PMID: 1460119. 19: Kragballe K, Jansén CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989;69(1):35-40. PubMed PMID: 2563606. 20: Seppälä J, Laulainen M, Reunala T. Comparison of etretinate (Tigason) and parenteral gold in the treatment of psoriatic arthropathy. Clin Rheumatol. 1988 Dec;7(4):498-503. PubMed PMID: 3149925.